Point72 Asset Management
ADCT icon

Point72 Asset Management’s ADC Therapeutics ADCT Stock Holding History

Point72 Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99K Buy
+26,400
New +$104K ﹤0.01% 3612

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's ADCT Position: Q1 2026 in Review

Point72 Asset Management reduced its ADC Therapeutics (ADCT) stake by 33% in Q1 2026, selling an estimated $6.44M and leaving 3,382,129 shares worth $12.7M. The position accounts for 0.02% of the portfolio, ranked #1079.

Point72 Asset Management first reported a position in ADCT in Q4 2022 and has held it in 5 quarters since. The position peaked at $32.5M in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Point72 Asset Management held 3,382,129 shares of ADC Therapeutics worth $12.7M as of Q1 2026.
  • Point72 Asset Management sold 1,632,488 ADC Therapeutics shares in Q1 2026, an estimated $6.44M.
  • ADC Therapeutics made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #1079 holding.
  • Point72 Asset Management first reported a position in ADC Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • Point72 Asset Management's ADC Therapeutics position peaked at $32.5M in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.